Microbot Medical Inc. (MBOT) News
Filter MBOT News Items
MBOT News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
MBOT News Highlights
- For MBOT, its 30 day story count is now at 4.
- Over the past 21 days, the trend for MBOT's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- The most mentioned tickers in articles about MBOT are DEC, GLP and PRE.
Latest MBOT News From Around the Web
Below are the latest news stories about MICROBOT MEDICAL INC that investors may wish to consider to help them evaluate MBOT as an investment opportunity.
Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were MetThe results of the study will support the Company’s IDE submission to the FDA to commence its human clinical studyBRAINTREE, Mass., Dec. 28, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels of planning, controlling, monitoring, and reporting, using a porcine model. As previously a |
Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY® Endovascular Robotic Surgical System for TeleroboticThe first phase in the collaboration will evaluate the current state of the LIBERTY® Robotic Surgical System in connection with remote enabled Endovascular treatmentsBRAINTREE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced it has entered into a collaboration agreement with Corewell Health™. The objective of the collaboration, which will take place in multiple phases, is to |
3 Stocks at the Forefront of Medical RoboticsEvery now and then, speculation – within carefully defined limits – may be appropriate, which brings us to the case for medical robotics stocks to buy. |
Microbot Medical Announces the Successful Completion of Its GLP Pivotal Pre-Clinical Study, a Critical Milestone for Its IDE submission to Commence Human Clinical StudyThe final histopathology and lab report supplements previous positive Company findings. The results of the study will support the Company’s IDE submission to the FDA to commence its human clinical study. BRAINTREE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announces the successful completion of its GLP pivotal pre-clinical study, done under the guidelines of FDA-required levels o |
Microbot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz- Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical, Regulatory and Commercial ActivitiesThe former Senior Medical Director for the Peripheral Interventions Division at Boston Scientific Corporation joins the Company as it transitions to the clinical and regulatory phase.BRAINTREE, Mass., Nov. 21, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Endovascular Robotic Surgical System, today announced the appointment of Dr. Juan Diaz-Cartelle as its new Chief Medical Officer (CMO), effective December 1, 2023. The hiring of Dr. Diaz-Car |
Microbot Medical Successfully Completed Integral Part of the Verification and Validation ProcessThe V&V process is an additional key milestone toward regulatory submission and is required to continue the regulatory process with the FDABRAINTREE, Mass., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Robotic Surgical System, today announces it had successfully completed the Electromagnetic Compatibility (EMC) testing section of the Verification and Validation (V&V) process. V&V are distinct procedures employed to ensure that a pro |
Microbot Medical Granted Registered Trademark from The U.S. Patent and Trademark OfficeBRAINTREE, Mass., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), the developer of the LIBERTY® Robotic Surgical System, the first single-use endovascular robotic system, today announced it had been granted a registered trademark from the US Patent and Trademark Office. The trademark “One & Done®” was given to the feature of the LIBERTY Robotic Surgical System which is being developed to integrate guidewires, microcatheters and other instruments required for complete endo |
Microbot Medical Reveals Successful Short Term Follow Up Outcomes from its Pivotal Pre-Clinical StudyFollow up visual examination three days after the procedures using the LIBERTY Robotic Surgical System, confirms 100% success rate in reaching the targets with no adverse eventsBRAINTREE, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Robotic Surgical System, today announces additional updates regarding positive outcomes of its previously announced pivotal pre-clinical study using the LIBERTY Robotic Surgical System. The pivota |
Microbot Medical Received Confirmation for the Commencement of Its CE Mark Approval Process During the First Half of 2024The Company’s designated Notified Body confirmed dates for conducting audits for ISO 13485 certification to ensure Microbot complies with the QMS requirements of the EU MDR The Company expects that the full CE Mark approval process of obtaining clearance of sales in the European Union for the LIBERTY® Robotic Surgical System, will be carried out in parallel with the FDA regulatory process BRAINTREE, Mass., Oct. 24, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the i |
Microbot Medical Announces Grant of Summary Judgment in its Favor and Dismissal of Counterclaim Against CompanyBRAINTREE, Mass., Oct. 19, 2023 (GLOBE NEWSWIRE) -- Microbot Medical Inc. (Nasdaq: MBOT), developer of the innovative LIBERTY® Robotic Surgical System, today announces that the United States District Court for the Southern District of New York, approved Microbot’s motion for summary judgment and dismissed with prejudice the previously announced Section 10(b) counterclaim brought by defendant as against Microbot in the action titled Microbot Medical Inc., Plaintiff v. Joseph Mona, Defendant. In i |